Chunk #15 — 2. Inhibitors of the NF-κB activation pathway — 2.3. Proteasome inhibitors and IκB ubiquitination blockers

Source

Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Embedded

yes

Text

Several serine protease inhibitors with chymotrypsin-like specificity, including DCIC, TPCK, TLCK, BTEE, APNE, are also able to block proteasome function. However, unlike other protease inhibitors that block only IκB degradation, serine protease inhibitors can block IκB phosphorylation as well as degradation. However, not all serine protease inhibitors can inhibit NF-κB activation [93–95].